
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxNSDJVWjJ3SXV5YlhWVGkyZlMzNzMybHh5YnJOd2xiLWY5V1VCYlBDcWVNd19ObGJZRnZvUXY2WUY4eUZiY2hfWE42SWliWnJWTTdKYlI0OGNQNDh5R1VEVWNoOVBTWXhJQ21mS0dtYnZuZlZqTlhrSTFuUFBKZ2Uya1JISXRXYm5XNGdkaFZkZ0VtNmsyXzZiRzNwSG1hVUVnT0dqRHg3XzlQZ3JrNEJYXzViTlNxcHcxUDhtdFBDemRaRVhTeFRQajdrcmhVTHU2ck1UakxkSzZlQnN3MHAxVGtEdzFLb0o3eS0xOWdvekg4cWNBY1pkY2M3TU9fREVIWEpvYUNjRzZ6QQ?oc=5" target="_blank">AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
